Argonautica Private Wealth Management Inc. Acquires 225 Shares of Stryker Co. (NYSE:SYK)

Argonautica Private Wealth Management Inc. increased its holdings in shares of Stryker Co. (NYSE:SYK) by 3.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,805 shares of the medical technology company’s stock after acquiring an additional 225 shares during the period. Stryker comprises about 0.9% of Argonautica Private Wealth Management Inc.’s investment portfolio, making the stock its 26th biggest position. Argonautica Private Wealth Management Inc.’s holdings in Stryker were worth $2,810,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Assenagon Asset Management S.A. boosted its stake in Stryker by 15.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 10,304 shares of the medical technology company’s stock valued at $3,722,000 after buying an additional 1,392 shares in the last quarter. Arkadios Wealth Advisors grew its holdings in shares of Stryker by 23.0% in the 3rd quarter. Arkadios Wealth Advisors now owns 732 shares of the medical technology company’s stock worth $265,000 after purchasing an additional 137 shares during the last quarter. J.W. Cole Advisors Inc. increased its position in shares of Stryker by 23.4% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 3,932 shares of the medical technology company’s stock worth $1,420,000 after purchasing an additional 746 shares in the last quarter. Autumn Glory Partners LLC lifted its holdings in Stryker by 139.8% during the 3rd quarter. Autumn Glory Partners LLC now owns 2,038 shares of the medical technology company’s stock valued at $737,000 after purchasing an additional 1,188 shares during the last quarter. Finally, Old Port Advisors boosted its position in Stryker by 5.2% in the third quarter. Old Port Advisors now owns 934 shares of the medical technology company’s stock valued at $337,000 after buying an additional 46 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on SYK shares. Truist Financial lifted their target price on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research note on Thursday, January 30th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Canaccord Genuity Group raised their target price on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Stifel Nicolaus upped their price target on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research note on Tuesday, February 18th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $422.15.

Stryker Stock Performance

Shares of SYK stock opened at $390.57 on Wednesday. The stock has a 50-day moving average of $378.78 and a 200-day moving average of $370.22. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The stock has a market cap of $149.03 billion, a PE ratio of 50.33, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the business earned $3.46 EPS. As a group, sell-side analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Insider Activity

In related news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.